Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
4(66.7%)
Early Phase 1
2(33.3%)
6Total
N/A(4)
Early Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT04381780Not ApplicableCompleted

Treatment of Fibromyalgia With Recovery Factors

Role: lead

NCT04599348Early Phase 1Unknown

Treatment of CFS and Fibromyalgia With HRG 80 Red Ginseng

Role: lead

NCT04598243Early Phase 1Unknown

Treatment of Fibromyalgia and CFS With Ribose, Ashwagandha, Rhodiola, Licorice, Schisandra and Green Tea Extract

Role: lead

NCT04381793Not ApplicableCompleted

Treatment of CFS & Fibromyalgia With Recovery Factors

Role: lead

NCT02260167Not ApplicableCompleted

Treatment of Alzheimer's and Dementia With the Metabolism, Infections, Nutrition, Drug Elimination (MIND) Protocol

Role: lead

NCT02260141Not ApplicableTerminated

Treating Alzheimer's and Dementia With D-ribose

Role: lead

All 6 trials loaded